Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis

Autor: Sebastian Steven, S.-Y. Weng, X.-Y. Wang, Thomas Klein, Detlef Schuppan, Michael Hausding, Andreas Daiber, Yong Ook Kim
Rok vydání: 2018
Předmět:
0301 basic medicine
medicine.medical_specialty
Physiology
Clinical Biochemistry
Anti-Inflammatory Agents
Gene Expression
Inflammation
Type 2 diabetes
030204 cardiovascular system & hematology
medicine.disease_cause
Biochemistry
Antioxidants
Proinflammatory cytokine
Mice
03 medical and health sciences
0302 clinical medicine
Non-alcoholic Fatty Liver Disease
Fibrosis
Internal medicine
medicine
Animals
Myeloid Cells
Molecular Biology
Dipeptidyl peptidase-4
General Environmental Science
Mice
Knockout

Dipeptidyl-Peptidase IV Inhibitors
business.industry
Macrophages
Cell Biology
Macrophage Activation
medicine.disease
Diet
Disease Models
Animal

Oxidative Stress
030104 developmental biology
Endocrinology
Liver
NADPH Oxidase 2
General Earth and Planetary Sciences
Tumor necrosis factor alpha
Steatosis
medicine.symptom
Reactive Oxygen Species
business
Biomarkers
Oxidative stress
Zdroj: Antioxidants & Redox Signaling. 28:87-109
ISSN: 1557-7716
1523-0864
Popis: Aims: Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis, and increased cardiovascular mortality. Dipeptidyl peptidase-4 inhibitors (gliptins) are indirect glucagon-like peptide 1 agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored. Results: In the methionine/choline-deficient (MCD) diet and Mdr2−/− models of NASH and liver fibrosis, treatment with sitagliptin and linagliptin significantly decreased parameters of steatosis and inflammation, which was accompanied by suppression of hepatic transcript levels reflecting metabolic inflammation and fibrosis, including SREBP-1c, FAS, TNFα, iNOS, α-SMA, Col1α1, and MMP-12. Moreover, gliptins reduced the number of liver infiltrating CD11b+Ly6Chi proinflammatory monocytes/macrophages and liver...
Databáze: OpenAIRE